GLYCAEMIC, ANTHROPOMETRIC, AND LIPID OUTCOMES OF CDC DM PACKAGE INTERVENTION IN 10 COMPLEX T2DM PATIENTS AT NAVI MUMBAI–PANVEL: A PILOT RETROSPECTIVE ANALYSIS

Dr. Rohit Sane, Dr. Gurudatta Amin, Dr. Pravin Ghadigaonkar, Dr. Nilesh Kulthe*, Dr. Priyanka Salwade

Background: Navi Mumbai-Panvel's DM Package cohort (n=10), while small, includes patients with complex comorbidities (DM+CAD, DM+IHD, multi-system disease) and 100% medication reduction documentation. This pilot analysis evaluates protocol efficacy in a complex, high-cardiovascular-risk diabetic population. Objective: To evaluate the effect of the Madhavbaug CDC Panchakarma-based multimodal protocol on glycaemic, anthropometric, cardiometabolic, and medication parameters exclusively in DM Package patients (n=10) at the Navi Mumbai (Panvel) Central RIC clinic. Methods: Retrospective observational study. 10 T2DM patients enrolled in the DM Package at Navi Mumbai (Panvel) Central RIC. Only DM Package care plans (CDC-SP Base/1/2/3, CDC-KP Base/1/2/3, DM-HTN 1/2/3) included. Paired Student's t-test (two-tailed) for within-group pre–post comparisons (p<0.05 significant). Descriptive statistics as mean ± SD. Results: RBS reduced significantly from 229.80±81.28 to 142.40±44.58 mg/dL (Δ −87.40 mg/dL, −38.0%, p<0.001, n=10). Weight fell by −4.78 kg (−6.4%, p=0.002). BMI −2.02 kg/m² (−6.9%, p=0.003). Abdominal girth −4.90 cm (−5.0%, p=0.003). DBP −5.40 mmHg (−6.1%, p=0.033). Total cholesterol showed a clinically meaningful reduction of −35.40 mg/dL (−18.1%, p=0.069, n=8). Triglycerides reduced by −27.05 mg/dL (−10.4%, p=0.040, n=8). All 10 patients achieved partial medication reduction (100% partial medication reduction rate). Conclusion: Despite its small sample (n=10), Navi Mumbai-Panvel's DM Package demonstrates exceptional results: RBS −38.0% (p<0.001), weight −6.4% (p=0.002), BMI −6.9% (p=0.003), abdominal girth −5.0% (p=0.003), triglycerides −10.4% (p=0.040), and DBP −6.1% (p=0.033). The 100% partial medication reduction rate and clinically meaningful lipid trends represent the strongest combined anthropometric and pharmacoeconomic outcomes in the Central RIC DM network.